Top

Published in:

01-12-2020 | Glioblastoma | Research article

Establishment of age group classification for risk stratification in glioma patients

Authors: Zhiying Lin, Runwei Yang, Kaishu Li, Guozhong Yi, Zhiyong Li, Jinglin Guo, Zhou Zhang, Peng Junxiang, Yawei Liu, Songtao Qi, Guanglong Huang

Published in: BMC Neurology | Issue 1/2020

Abstract

Background

Age is associated with the prognosis of glioma patients, but there is no uniform standard of age-group classification to evaluate the prognosis of glioma patients. In this study, we aimed to establish an age group classification for risk stratification in glioma patients.

Methods

1502 patients diagnosed with gliomas at Nanfang Hospital between 2000 and 2018 were enrolled. The WHO grade of glioma was used as a dependent variable to evaluate the effect of age on risk stratification. The evaluation model was established by logistic regression, and the Akaike information criterion (AIC) value of the model was used to determine the optimal cutoff points for age-classification. The differences in gender, WHO grade, pathological subtype, tumor cell differentiation, tumor size, tumor location, and molecular markers between different age groups were analyzed. The molecular markers included GFAP, EMA, MGMT, P53, NeuN, Oligo2, EGFR, VEGF, IDH1, Ki-67, PR, CD3, H3K27M, TS, and 1p/19q status.

Results

The proportion of men with glioma was higher than that of women with glioma (58.3% vs 41.7%). Analysis of age showed that appropriate classifications of age group were 0–14 years old (pediatric group), 15–47 years old (youth group), 48–63 years old (middle-aged group), and ≥ 64 years old (elderly group).The proportions of glioblastoma and large tumor size (4–6 cm) increased with age (p = 0.000, p = 0.018, respectively). Analysis of the pathological molecular markers across the four age groups showed that the proportion of patients with larger than 10% area of Ki-67 expression or positive PR expression increased with age (p = 0.000, p = 0.017, respectively).

Conclusions

Appropriate classifications of the age group for risk stratification are 0–14 years old (pediatric group), 15–47 years old (young group), 48–63 years old (middle age group) and ≥ 64 years old (elderly group). This age group classification is effective in evaluating the risk of glioblastoma in glioma patients.

Available only for authorised users

de Robles P, Fiest KM, Frolkis AD, Pringsheim T, Atta C, St Germaine-Smith C, et al. The worldwide incidence and prevalence of primary brain tumors: a systematic review and meta-analysis. Neuro-Oncology. 2015;17(6):776–83. https://doi.org/10.1093/neuonc/nou283.CrossRefPubMed

Weller M, Wick W, Aldape K, Brada M, Berger M, Pfister SM, et al. Glioma. Nat Rev Dis Primers. 2015;1:15017. https://doi.org/10.1038/nrdp.2015.17.CrossRefPubMed

Ostrom QT, Gittleman H, Liao P, Vecchione-Koval T, Wolinsky Y, Kruchko C, et al. CBTRUS Statistical Report: Primary brain and other central nervous system tumors diagnosed in the United States in 2010–2014. Neuro Oncol. 2017;19(suppl_5):v1–v88. https://doi.org/10.1093/neuonc/nox158.CrossRefPubMedPubMedCentral

Usinskiene J, Ulyte A, Bjornerud A, Venius J, Katsaros VK, Rynkeviciene R, et al. Optimal differentiation of high- and low-grade glioma and metastasis: a meta-analysis of perfusion, diffusion, and spectroscopy metrics. Neuroradiology. 2016;58(4):339–50. https://doi.org/10.1007/s00234-016-1642-9.CrossRefPubMed

Thakkar JP, Dolecek TA, Horbinski C, Ostrom QT, Lightner DD, Barnholtz-Sloan JS, et al. Epidemiologic and molecular prognostic review of glioblastoma. Cancer Epidemiol Biomark Prev. 2014;23(10):1985–96. https://doi.org/10.1158/1055-9965.EPI-14-0275.CrossRef

Rasmussen BK, Hansen S, Laursen RJ, Kosteljanetz M, Schultz H, Norgard BM, et al. Epidemiology of glioma: clinical characteristics, symptoms, and predictors of glioma patients grade I-IV in the the Danish Neuro-oncology registry. J Neuro-Oncol. 2017;135(3):571–9. https://doi.org/10.1007/s11060-017-2607-5.CrossRef

Arora RS, Alston RD, Eden TO, Estlin EJ, Moran A, Birch JM. Age-incidence patterns of primary CNS tumors in children, adolescents, and adults in England. Neuro-Oncology. 2009;11(4):403–13. https://doi.org/10.1215/15228517-2008-097.CrossRefPubMedPubMedCentral

Hochberg FH, Atai NA, Gonda D, Hughes MS, Mawejje B, Balaj L, et al. Glioma diagnostics and biomarkers: an ongoing challenge in the field of medicine and science. Expert Rev Mol Diagn. 2014;14(4):439–52. https://doi.org/10.1586/14737159.2014.905202.CrossRefPubMedPubMedCentral

Jones C, Perryman L, Hargrave D. Paediatric and adult malignant glioma: close relatives or distant cousins? Nat Rev Clin Oncol. 2012;9(7):400–13. https://doi.org/10.1038/nrclinonc.2012.87.CrossRefPubMed

10.

Qaddoumi I, Sultan I, Gajjar A. Outcome and prognostic features in pediatric gliomas: a review of 6212 cases from the surveillance, epidemiology, and end results database. Cancer. 2009;115(24):5761–70. https://doi.org/10.1002/cncr.24663.CrossRefPubMed

11.

Yang LS, Huang FP, Zheng K, Zhang HS, Zhou X, Bao XH, et al. Factors affecting prognosis of patients with intracranial anaplastic oligodendrogliomas: a single institutional review of 70 patients. J Neuro-Oncol. 2010;100(1):113–20. https://doi.org/10.1007/s11060-010-0146-4.CrossRef

12.

Fuller CE, Schmidt RE, Roth KA, Burger PC, Scheithauer BW, Banerjee R, et al. Clinical utility of fluorescence in situ hybridization (FISH) in morphologically ambiguous gliomas with hybrid oligodendroglial/astrocytic features. J Neuropathol Exp Neurol. 2003;62(11):1118–28. https://doi.org/10.1093/jnen/62.11.1118.CrossRefPubMed

13.

Ozyigit G, Onal C, Gurkaynak M, Soylemezoglu F, Zorlu F. Postoperative radiotherapy and chemotherapy in the management of oligodendroglioma: single institutional review of 88 patients. J Neuro-Oncol. 2005;75(2):189–93. https://doi.org/10.1007/s11060-005-2057-3.CrossRef

14.

Weller M, van den Bent M, Tonn JC, Stupp R, Preusser M, Cohen-Jonathan-Moyal E, et al. European Association for Neuro-Oncology (EANO) guideline on the diagnosis and treatment of adult astrocytic and oligodendroglial gliomas. Lancet Oncol. 2017;18(6):e315–e29. https://doi.org/10.1016/s1470-2045(17)30194-8.CrossRefPubMed

15.

Garzon M, Garcia-Fructuoso G, Sunol M, Mora J, Cruz O. Low-grade gliomas in children: single institutional experience in 198 cases. Childs Nerv Syst. 2015;31(9):1447–59. https://doi.org/10.1007/s00381-015-2800-9.CrossRefPubMed

16.

Castet F, Alanya E, Vidal N, Izquierdo C, Mesia C, Ducray F, et al. Contrast-enhancement in supratentorial low-grade gliomas: a classic prognostic factor in the molecular age. J Neuro-Oncol. 2019;143(3):515–23. https://doi.org/10.1007/s11060-019-03183-2.CrossRef

17.

Chen JW, Zhou CF, Lin ZX. The influence of different classification standards of age groups on prognosis in high-grade hemispheric glioma patients. J Neurol Sci. 2015;356(1–2):148–52. https://doi.org/10.1016/j.jns.2015.06.036.CrossRefPubMed

18.

Allahdini F, Amirjamshidi A, Reza-Zarei M, Abdollahi M. Evaluating the prognostic factors effective on the outcome of patients with glioblastoma multiformis: does maximal resection of the tumor lengthen the median survival? World Neurosurg. 2010;73(2):128–34; discussion e16. https://doi.org/10.1016/j.wneu.2009.06.001.CrossRefPubMed

19.

Seidel C, Dörner N, Osswald M, Wick A, Platten M, Bendszus M, et al. Does age matter? - a MRI study on peritumoral edema in newly diagnosed primary glioblastoma. BMC Cancer. 2011;11:1. https://doi.org/10.1186/1471-2407-11-127.CrossRef

20.

Ohgaki H, Dessen P, Jourde B, Horstmann S, Nishikawa T, Di Patre PL, et al. Genetic pathways to glioblastoma: a population-based study. Cancer Res. 2004;64(19):6892–9. https://doi.org/10.1158/0008-5472.CAN-04-1337.CrossRefPubMed

21.

Smith JS, Tachibana I, Passe SM, Huntley BK, Borell TJ, Iturria N, et al. PTEN mutation, EGFR amplification, and outcome in patients with anaplastic astrocytoma and glioblastoma multiforme. J Natl Cancer Inst. 2001;93(16):1246–56. https://doi.org/10.1093/jnci/93.16.1246.CrossRefPubMed

22.

Burger PC, Green SB. Patient age, histologic features, and length of survival in patients with glioblastoma multiforme. Cancer. 1987;59(9):1617–25. https://doi.org/10.1002/1097-0142(19870501)59:9<1617::aid-cncr2820590916>3.0.co;2-x.CrossRefPubMed

23.

Paugh BS, Qu C, Jones C, Liu Z, Adamowicz-Brice M, Zhang J, et al. Integrated molecular genetic profiling of pediatric high-grade gliomas reveals key differences with the adult disease. J Clin Oncol. 2010;28(18):3061–8. https://doi.org/10.1200/JCO.2009.26.7252.CrossRefPubMedPubMedCentral

24.

Broniscer A, Baker SJ, West AN, Fraser MM, Proko E, Kocak M, et al. Clinical and molecular characteristics of malignant transformation of low-grade glioma in children. J Clin Oncol. 2007;25(6):682–9. https://doi.org/10.1200/JCO.2006.06.8213.CrossRefPubMed

25.

Qu HQ, Jacob K, Fatet S, Ge B, Barnett D, Delattre O, et al. Genome-wide profiling using single-nucleotide polymorphism arrays identifies novel chromosomal imbalances in pediatric glioblastomas. Neuro-Oncology. 2010;12(2):153–63. https://doi.org/10.1093/neuonc/nop001.CrossRefPubMedPubMedCentral

26.

Bandopadhayay P, Bergthold G, London WB, Goumnerova LC, Morales La Madrid A, Marcus KJ, et al. Long-term outcome of 4,040 children diagnosed with pediatric low-grade gliomas: An analysis of the Surveillance Epidemiology and End Results (SEER) database. Pediatric Blood Cancer. 2014;61(7):1173–9. https://doi.org/10.1002/pbc.24958.CrossRefPubMedPubMedCentral

27.

Di Cristofori A, Zarino B, Fanizzi C, Fornara GA, Bertani G, Rampini P, et al. Analysis of factors influencing the access to concomitant chemo-radiotherapy in elderly patients with high grade gliomas: role of MMSE, age and tumor volume. J Neuro-Oncol. 2017;134(2):377–85. https://doi.org/10.1007/s11060-017-2537-2.CrossRef

28.

Krishnatry R, Zhukova N, Guerreiro Stucklin AS, Pole JD, Mistry M, Fried I, et al. Clinical and treatment factors determining long-term outcomes for adult survivors of childhood low-grade glioma: a population-based study. Cancer. 2016;122(8):1261–9. https://doi.org/10.1002/cncr.29907.CrossRefPubMed

29.

Lowry JK, Snyder JJ, Lowry PW. Brain tumors in the elderly: recent trends in a Minnesota cohort study. Arch Neurol. 1998;55(7):922–8.CrossRefPubMed

30.

Barnholtz-Sloan JS, Williams VL, Maldonado JL, Shahani D, Stockwell HG, Chamberlain M, et al. Patterns of care and outcomes among elderly individuals with primary malignant astrocytoma. J Neurosurg. 2008;108(4):642–8. https://doi.org/10.3171/jns/2008/108/4/0642.CrossRefPubMed

31.

Perry JR, Laperriere N, O'Callaghan CJ, Brandes AA, Menten J, Phillips C, et al. Short-course radiation plus Temozolomide in elderly patients with Glioblastoma. N Engl J Med. 2017;376(11):1027–37. https://doi.org/10.1056/NEJMoa1611977.CrossRefPubMed

32.

Zapotocky M, Ramaswamy V, Lassaletta A, Bouffet E. Adolescents and young adults with brain tumors in the context of molecular advances in neuro-oncology. Pediatr Blood Cancer. 2018;65:2. https://doi.org/10.1002/pbc.26861.CrossRef

33.

Li SW, Qiu XG, Chen BS, Zhang W, Ren H, Wang ZC, et al. Prognostic factors influencing clinical outcomes of glioblastoma multiforme. Chin Med J. 2009;122(11):1245–9.PubMed

34.

Verhaak RG, Hoadley KA, Purdom E, Wang V, Qi Y, Wilkerson MD, et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell. 2010;17(1):98–110. https://doi.org/10.1016/j.ccr.2009.12.020.CrossRefPubMedPubMedCentral

35.

Patel AP, Tirosh I, Trombetta JJ, Shalek AK, Gillespie SM, Wakimoto H, et al. Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma. Science (New York, NY). 2014;344(6190):1396–401. https://doi.org/10.1126/science.1254257.CrossRef

36.

Wang Q, Hu B, Hu X, Kim H, Squatrito M, Scarpace L, et al. Tumor Evolution of Glioma-Intrinsic Gene Expression Subtypes Associates with Immunological Changes in the Microenvironment. Cancer Cell. 2017;32(1):42–56 e6. https://doi.org/10.1016/j.ccell.2017.06.003.CrossRefPubMedPubMedCentral

37.

Thewjitcharoen Y, Krittiyawong S, Butadej S, Nakasatien S, Polchart S, Junyangdikul P, et al. De-differentiation of papillary thyroid carcinoma into squamous cell carcinoma in an elderly patient: A case report. Medicine (Baltimore). 2020;99(16):e19892. https://doi.org/10.1097/MD.0000000000019892.CrossRef

38.

Ito Y, Takeda T, Sakon M, Tsujimoto M, Higashiyama S, Noda K, et al. Expression and clinical significance of erb-B receptor family in hepatocellular carcinoma. Br J Cancer. 2001;84(10):1377–83. https://doi.org/10.1054/bjoc.2000.1580.CrossRefPubMedPubMedCentral

39.

Batchelor TT, Betensky RA, Esposito JM, Pham LD, Dorfman MV, Piscatelli N, et al. Age-dependent prognostic effects of genetic alterations in glioblastoma. Clin Cancer Res. 2004;10(1 Pt 1):228–33. https://doi.org/10.1158/1078-0432.ccr-0841-3.CrossRefPubMed

40.

Kawasoe T, Takeshima H, Yamashita S, Mizuguchi S, Fukushima T, Yokogami K, et al. Detection of p53 mutations in proliferating vascular cells in glioblastoma multiforme. J Neurosurg. 2015;122(2):317–23. https://doi.org/10.3171/2014.10.JNS132159.CrossRefPubMed

41.

Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 2005;352(10):997–1003. https://doi.org/10.1056/NEJMoa043331.CrossRefPubMed

42.

Gonzalez-Aguero G, Ondarza R, Gamboa-Dominguez A, Cerbon MA, Camacho-Arroyo I. Progesterone receptor isoforms expression pattern in human astrocytomas. Brain Res Bull. 2001;56(1):43–8. https://doi.org/10.1016/s0361-9230(01)00590-1.CrossRefPubMed

43.

Yan H, Parsons DW, Jin G, McLendon R, Rasheed BA, Yuan W, et al. IDH1 and IDH2 mutations in gliomas. N Engl J Med. 2009;360(8):765–73. https://doi.org/10.1056/NEJMoa0808710.CrossRefPubMedPubMedCentral

44.

Schwartzentruber J, Korshunov A, Liu XY, Jones DT, Pfaff E, Jacob K, et al. Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma. Nature. 2012;482(7384):226–31. https://doi.org/10.1038/nature10833.CrossRefPubMed

45.

Karsy M, Guan J, Cohen AL, Jensen RL, Colman H. New Molecular Considerations for Glioma: IDH, ATRX, BRAF, TERT, H3 K27M. Curr Neurol Neurosci Rep. 2017;17(2):19. https://doi.org/10.1007/s11910-017-0722-5.CrossRefPubMed

46.

Zhao F, Zhang J, Li P, Zhou Q, Zhang S, Zhao C, et al. Prognostic value of Ki-67 index in adult medulloblastoma after accounting for molecular subgroup: a retrospective clinical and molecular analysis. J Neuro-Oncol. 2018;139(2):333–40. https://doi.org/10.1007/s11060-018-2865-x.CrossRef

Title: Establishment of age group classification for risk stratification in glioma patients
Authors: Zhiying Lin
Runwei Yang
Kaishu Li
Guozhong Yi
Zhiyong Li
Jinglin Guo
Zhou Zhang
Peng Junxiang
Yawei Liu
Songtao Qi
Guanglong Huang
Publication date: 01-12-2020
Publisher: BioMed Central
Keywords: Glioblastoma
Astrocytoma
Glioma
Glioma
Astrocytoma
Glioblastoma
Astrocytoma
Glioblastoma
Oligodendroglioma
Glioma
Published in: BMC Neurology / Issue 1/2020
Electronic ISSN: 1471-2377
DOI: https://doi.org/10.1186/s12883-020-01888-w

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Establishment of age group classification for risk stratification in glioma patients

Abstract

Background

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2020

Pain in children and adolescents with cerebral palsy – a cross-sectional register study of 3545 individuals

The impact of time from injury to surgery in functional recovery of traumatic acute subdural hematoma

A systematic review of active group-based dance, singing, music therapy and theatrical interventions for quality of life, functional communication, speech, motor function and cognitive status in people with Parkinson’s disease

Reduced serum levels of pro-inflammatory chemokines in fragile X syndrome

Risk of Parkinson’s disease following gout: a population-based retrospective cohort study in Taiwan

Prior treatment status: impact on the efficacy and safety of teriflunomide in multiple sclerosis